Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Acquisitions & Divestments: 2015-2024

Historic Change in Acquisitions & Divestments for Iovance Biotherapeutics (IOVA) over the last 10 years, with Dec 2024 value amounting to $428.0 million.

  • Iovance Biotherapeutics' Change in Acquisitions & Divestments rose 9.09% to $120.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $446.0 million, marking a year-over-year increase of 27.43%. This contributed to the annual value of $428.0 million for FY2024, which is 49.87% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Change in Acquisitions & Divestments stood at $428.0 million for FY2024, which was up 49.87% from $285.6 million recorded in FY2023.
  • Over the past 5 years, Iovance Biotherapeutics' Change in Acquisitions & Divestments peaked at $762.9 million during FY2021, and registered a low of $285.6 million during FY2023.
  • Its 3-year average for Change in Acquisitions & Divestments is $412.1 million, with a median of $428.0 million in 2024.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first crashed by 45.36% in 2023, then skyrocketed by 49.87% in 2024.
  • Iovance Biotherapeutics' Change in Acquisitions & Divestments (Yearly) stood at $676.6 million in 2020, then climbed by 12.76% to $762.9 million in 2021, then tumbled by 31.49% to $522.7 million in 2022, then tumbled by 45.36% to $285.6 million in 2023, then surged by 49.87% to $428.0 million in 2024.